A Phase 3 interventional study of Xaluritamig and Abiraterone in Metastatic Castration-resistant Prostate Cancer, sponsored by Amgen. Active, not recruiting at 164 sites in 22 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.
Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 5th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 in phase 3, and was the 20th registered.
7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia
Ages 18+ · Men only
Amgen · Sites in United States, Australia, Austria and 15 more countries
Ages 18+ · Men only
Amgen · Sites in United States, Germany
Ages 18+ · Men only
Amgen · Sites in United States, Australia, China and 7 more countries
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 4 · Phase 3 9
First in 1999; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 707 is above the median of 60 across 5,353 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 64 across the 21 interventional studies, 1,262 across the 1 observational. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
3 of the studies in Prostatic Neoplasms by Amgen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06613100AmgenEvaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | 2027-02-17 |
| NCT06555796AmgenEvaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | 2027-03-13 |
| NCT07140900AmgenStudy Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer | 2027-10-27 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Prostatic Neoplasms by Amgen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
This study's enrollment of 707 is above the median of 60 across 5,353 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
Key Exclusion Criteria:
Prior \& Concomitant Therapy:
Disease Related:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with metastatic castration-resistant prostate cancer (mCRPC) will be randomized to receive Xaluritamig as an intravenous (IV) infusion.
Drug: Xaluritamig
Participants with mCRPC will be randomized to receive cabazitaxel as an IV infusion, or a second androgen receptor-directed therapy of either abiraterone as oral tablets, or enzalutamide as oral tablets at the investigator's discretion.
Drug: Abiraterone · Drug: Enzalutamide · Drug: Cabazitaxel
Short-term IV infusion
Oral tablets
Oral tablets
IV infusion
Overall Survival (OS)
Time frame: Up to approximately 53 months
Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)
Time frame: Up to approximately 53 months
Objective Response Rate per Modified RECIST v1.1 as Assessed by BICR
Time frame: Up to approximately 53 months
Duration of Response (DOR) per Modified RECIST v1.1 as Assessed by BICR
Time frame: Up to approximately 53 months
Disease Control Rate per Modified RECIST v1.1 as Assessed by BICR
Time frame: Up to approximately 53 months
Time to Response (TTR) per Modified RECIST v1.1 as Assessed by BICR
Time frame: Up to approximately 53 months
Time to First Symptomatic Skeletal Events (SSE)
Time frame: Up to approximately 53 months
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to approximately 53 months
Change from Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain Score
Time frame: Baseline and approximately 53 months
Change from Baseline in BPI-SF Pain Intensity Scale Score
Time frame: Baseline and approximately 53 months
Change from Baseline in BPI-SF Pain Interference Scale Score
Time frame: Baseline and approximately 53 months
Change from baseline in the European Quality of Life 5 Domain 5 Level Scale (EQ-5D-5L) Utility Score
Time frame: Baseline and approximately 53 months
Change from baseline in the EQ-5D-5L Visual Analogue Scale (VAS)
Time frame: Baseline and approximately 53 months
Change from Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score and Subscale Score
Time frame: Baseline and approximately 53 months
Time to Worsening in BPI-SF Worst Pain Score
Time frame: Up to approximately 53 months
Time to Worsening in BPI-SF Pain Intensity Scale Score
Time frame: Up to approximately 53 months
Time to Worsening in BPI-SF Pain Interference Scale Score
Time frame: Up to approximately 53 months
Time to Worsening in FACT-P Total Score
Time frame: Up to approximately 53 months
Time to Pain Improvement in Participants with Moderate/Severe Pain at Baseline
Time frame: Up to approximately 53 months
Time to Pain Improvement after Worsening in BPI-SF Pain Intensity Scale Score
Time frame: Up to approximately 53 months
Time to Pain Improvement after Worsening in BPI-SF Pain Interference Scale
Time frame: Up to approximately 53 months
Number of Patient-Reported Symptomatic AEs per Patient-reported Outcome - Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library
Time frame: Up to approximately 53 months
Patient-Reported Summary Scores for Overall Bother of Side Effects per FACT-P
Time frame: Up to approximately 53 months
Percentage of Participants Achieving a ≥50% Reduction in Prostate-specific Antigen (PSA) (PSA50)
Time frame: Up to approximately 53 months
Percentage of Participants Achieving a ≥90% Reduction in PSA (PSA90)
Time frame: Up to approximately 53 months
Maximum Serum Concentration (Cmax) of Xaluritamig
Time frame: Up to approximately 53 months
Time to Cmax (Tmax) of Xaluritamig
Time frame: Up to approximately 53 months
Minimum Serum Concentration (Cmin) of Xaluritamig
Time frame: Up to approximately 53 months
Area Under the Concentration-time Curve (AUC) of Xaluritamig
Time frame: Up to approximately 53 months
Accumulation Following Multiple Dosing of Xaluritamig
Time frame: Up to approximately 53 months
Half-life (t1/2) of Xaluritamig
Time frame: Up to approximately 53 months
Number of Participants with Anti-xaluritamig Antibody
Time frame: Up to approximately 53 months
Showing the first 100 of 164 sites across 22 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Dec 2024 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 48 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Xaluritamig